Dynavax Technologies (NASDAQ:DVAX) Trading Down 3.5%

Dynavax Technologies Co. (NASDAQ:DVAX)’s share price was down 3.5% during mid-day trading on Monday . The stock traded as low as $10.59 and last traded at $10.64. Approximately 130,302 shares changed hands during trading, a decline of 94% from the average daily volume of 2,098,353 shares. The stock had previously closed at $11.03.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on DVAX shares. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. The Goldman Sachs Group dropped their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Dynavax Technologies has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Price Performance

The company’s fifty day moving average price is $11.00 and its 200 day moving average price is $11.56. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 186.50 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. During the same period in the previous year, the business posted $0.03 EPS. Equities research analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Congress Asset Management Co. MA lifted its stake in shares of Dynavax Technologies by 0.4% in the 4th quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company’s stock worth $3,175,000 after acquiring an additional 799 shares during the period. Diversified Trust Co lifted its stake in shares of Dynavax Technologies by 3.2% in the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 925 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 1,172 shares during the period. SummerHaven Investment Management LLC lifted its stake in shares of Dynavax Technologies by 2.4% in the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 1,303 shares during the period. Finally, Texas Permanent School Fund Corp raised its holdings in shares of Dynavax Technologies by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after purchasing an additional 1,467 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.